Where is Arcutis Biotherapeutics, Inc headquartered?

Arcutis Biotherapeutics is recorded with headquarters in Westlake Village, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Arcutis Biotherapeutics, Inc publicly traded?

Yes — Arcutis Biotherapeutics, Inc is listed as a public company with ticker ARQT on NYSE in SEC EDGAR-derived records.

What drugs are associated with Arcutis Biotherapeutics, Inc?

We link 1 drug profile(s) where Arcutis Biotherapeutics, Inc appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Arcutis Biotherapeutics, Inc sponsoring?

Arcutis Biotherapeutics, Inc is linked to 27 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Arcutis Biotherapeutics, Inc as applicant?

30 USPTO PatentsView record(s) name Arcutis Biotherapeutics or a normalized variant as applicant.

What pipeline phases does Arcutis Biotherapeutics, Inc have in our database?

Phase distribution from linked programs: phase 2: 13, phase 3: 9, phase 1: 4, approved: 1.

How many US-approved drugs are linked to Arcutis Biotherapeutics, Inc?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Arcutis Biotherapeutics, Inc hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Arcutis Biotherapeutics, Inc?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Arcutis Biotherapeutics, Inc data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Arcutis Biotherapeutics Pharmaceuticals Company Profile

Name: Arcutis Biotherapeutics intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 2945 Townsgate Rd, Westlake Village, California 91361, US
Founded: 2016
Employees: 427
Programs: 27
Drugs: 3
Patents: 30

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Arcutis Biotherapeutics, Inc is a pharma organization headquartered in Westlake Village, USA. It trades on NYSE under ticker ARQT. Primary therapeutic focus areas include Atopic Dermatitis Eczema, Plaque Psoriasis, Chronic Plaque Psoriasis, Psoriasis, Seborrheic Dermatitis. NovaPharmaNews links 27 clinical program(s), 1 drug profile(s), and 30 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (13), phase 3 (9), phase 1 (4).

Company snapshot

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat

2 approved product(s) across US/EU regulatory metadata.
27 active pipeline program(s) linked via ClinicalTrials.gov.
30 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Arcutis Biotherapeutics. Not investment advice.

Top assets

View drugs (3) View projects (27)

Lead pipeline drugs

epinephrine
approved
nemolizumab
Marketed / approved
roflumilast
approved
ARQ-151 0.3% cream Chronic Plaque Psoriasis
Phase 3

Active clinical programs

ARQ-151 0.3% cream Chronic Plaque Psoriasis
Phase 3
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% Atopic Dermatitis Eczema
Phase 3
Roflumilast 0.3% cream Chronic Plaque Psoriasis
Phase 3
Roflumilast Cream Atopic Dermatitis Eczema
Phase 3

Momentum

Proprietary activity score for Arcutis Biotherapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 28 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Provectus Biopharmaceuticals

TA overlap score 32.4
Peer + 0 momentum

Incyte

TA overlap score 30.6
Peer + 0 momentum

Forteo

TA overlap score 21

Recent activity

Latest pipeline, patent, and corporate events for Arcutis Biotherapeutics.

Jun 8, 2026 Clinical update
Topical roflumilast — Phase 3
Jun 8, 2026 Clinical update
Topical roflumilast 0.3% foam — Phase 2
Jun 8, 2026 Clinical update
Roflumilast Cream 0.15% — Approved
May 23, 2026 Clinical update
ARQ-151 0.3% cream — Phase 3
May 23, 2026 Clinical update
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Arcutis Biotherapeutics?

Arcutis Biotherapeutics, Inc is a pharma organization headquartered in Westlake Village, USA. It trades on NYSE under ticker ARQT. Primary therapeutic focus areas include Atopic Dermatitis Eczema, Plaque Psoriasis, Chronic Plaque Psoriasis, Psoriasis, Seborrheic Dermatitis. NovaP
Is Arcutis Biotherapeutics publicly traded?

Yes. Arcutis Biotherapeutics is listed with ticker ARQT on NYSE per SEC EDGAR records linked on this profile.
What drugs does Arcutis Biotherapeutics develop or market?

We link 3 drug profile(s) where Arcutis Biotherapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/arcutis-biotherapeutics#company-drugs.
What are the latest developments for Arcutis Biotherapeutics?

In the last 12 months our linked public records show 27 trial program update(s) and 3 US patent grant(s) tied to this profile.
What therapeutic areas does Arcutis Biotherapeutics focus on?

Arcutis Biotherapeutics focuses on Atopic Dermatitis Eczema, Plaque Psoriasis, Chronic Plaque Psoriasis based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Cardiology